Earnings ·
Axsome Therapeutics reported second quarter 2026 financial results with total net product revenue of $218.4 million, a…
AXSMAxsome Therapeutics, Inc.
Axsome Therapeutics reported second quarter 2026 financial results with total net product revenue of $218.4 million, a 46% year-over-year increase driven by strong demand for its CNS portfolio. AUVELITY sales reached $180.3 million (51% growth) following its June 2026 launch for Alzheimer’s disease agitation, while SUNOSI revenue grew 20% to $35.8 million and SYMBRAVO sales increased 461% to $2.3 million. The company reported a net loss of $51.3 million, or $(0.99) per share, compared to a $48.0 million loss in the prior year period. Axsome also announced that its NDA for AXS-12 for cataplexy was accepted by the FDA with a PDUFA date of May 1, 2027, and initiated Phase 3 trials for solriamfetol in pediatric ADHD. The company operates as a biopharmaceutical firm focused on developing treatments for central nervous system disorders.